The University of Aberdeen has been awarded £5.1m from the Wellcome Trust to lead a major UK collaboration to tackle the problem of fungal infections.The Aberdeen Fungal Group – the biggest fungal research group in Britain and one of the largest in the world – will head the new Medical Mycology and Fungal Immunology Consortium, which will also be supported by scientists at Imperial College London and the Universities of Newcastle, Manchester, Birmingham, Kent, Exeter and other UK institutions.The Consortium’s aims include:Taking research from the lab into the clinic and pharmaceutical industry to develop better diagnostics and more effective treatments for fungal infectionsLeading a research and training programme, harnessing UK expertise, to understand fungal infections and immunity to these diseases better and to train a new generation of scientists and cliniciansPromoting greater public awareness of fungal infections using channels such as You Tube and the Internet.Professor Neil Gow, chair in Microbiology at the University of Aberdeen, and director of the Consortium, said: ‘People are very familiar with superficial fungal infections, such as ringworm and athlete’s foot, which affect approximately a quarter of the world’s population and are usually easily treated.‘Fungal infections of the mouth and genitals are also common – thrush is estimated to affect 75 million women each year – while oral infections are common in babies and denture wearers. Again these can be treated relatively easily in healthy patients.‘However, invasive fungal infections in the major organs of the body are associated with high mortality rates.’Gow said cancer, trauma and HIV patients, and those who have undergone bone and organ transplants, are more susceptible to fungal infections and new strategies are desperately needed to combat them as they can be life-threatening.Professor Al Brown, a chair in Microbiology at the University of Aberdeen and Co-Director, added: ‘There are a number of different fungal pathogens but the big four that pose the most risk are Candida, Aspergillus, Pneumocystis and Cryptococcus. Each year Candida is estimated to cause 400,000 life-threatening systemic infections of the body’s major organs.‘We need better treatment for fungal infections, better ways of diagnosing the problem and better understanding of its immunology and pathology and those are the challenges our consortium will tackle.’The Consortium will also create 10 international PhD studentships, three clinical PhD studentships and six post-doctoral research assistant posts that will be spread across UK institutions.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment